(±)16(17)-EpDPA T37235

Product Introduction
Bioactivity


英文名: (±)16(17)-EpDPA

描述: EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)16(17)-EpDPA is the DHA homolog of (±)14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of DHA. The EDHF activity of (±)16(17)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.[4]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL
DMF : 50 mg/mL
PBS (pH 7.2) : 1 mg/mL
Ethanol : 50 mg/mL


关键字: 16(17)-EpDPA | 16,17 EDP | 16,17-epoxy Docosapentaenoic Acid | (±)16(17) EpDPA | 16,17-EpDPE | (±)16(17)EpDPA | 16,17-epoxy DPA

(±)16(17)-EpDPA T37235信息由TargetMol中国为您提供，如您想了解更多关于(±)16(17)-EpDPA T37235报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途